Pompe Disease Market in the US 2015-2019

Pompe disease industry analysis in the US

Pompe disease is a type of lysosomal storage disease (LSD) that is caused by mutations in the GAA gene. These mutations inhibit the action of GAA, which is an enzyme responsible for catabolizing glycogen. The market for Pompe disease in the US is estimated to show healthy growth during the forecast period and is positively influenced by factors like the reimbursement of treatment expenses by governments and vendors in some countries. These factors propel market growth during the forecast period and result in its healthy CAGR of more than 10% by 2019.

Based on the Pompe disease industry insights, eminent factors, such as the high-unmet medical needs of patients, to drive market growth during the forecast period. Drugs like Myozyme and Lumizyme fail to improve the neurological symptoms associated with the disease. This unavailability of a drug that is safe, effective, and less expensive is expected to bolster market growth during the forecast period.

Types of Pompe disease

• Infantile-onset Pompe disease
• Adult-onset Pompe disease